Physicians' Academy for Cardiovascular Education

Recent advances in lowering CV risk with antidiabetic agents

Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott

Video navigation menu

  • What can be done about the increasing prevalance of diabetes and associated CV disease? 0:15
  • Assessing CV benefit of diabetes agents in large CV outcomes trials 2:41
  • Targeting the SGLT2 transporter to lower blood glucose exerts various effects 3:24
  • Are the EMPA-REG OUTCOMES results reproducible? 7:27
  • Where are we now with anti-diabetic treatment in relation to lowering CV risk? 8:36